A Co-Inhibitory Alliance in Myeloid Leukemia: TIM-3/Galectin-9 Complex as a New Target for Checkpoint Blockade Therapy
Main Authors: | M. Alper Kursunel, Gunes Esendagli |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-09-01
|
Series: | EBioMedicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S235239641730316X |
Similar Items
-
The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells
by: Isabel Gonçalves Silva, et al.
Published: (2017-08-01) -
TIM-3/Gal-9 signaling is the molecular target for human myeloid leukemia treatment
by: Koichi Akashi
Published: (2020-10-01) -
TIM-3 does not act as a receptor for galectin-9.
by: Judith Leitner, et al.
Published: (2013-03-01) -
Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia
by: Krzysztof Giannopoulos
Published: (2019-02-01) -
Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
by: Emeric Limagne, et al.
Published: (2019-04-01)